Natera
Natera Reports Strong Q2 Revenue Gains Driven Largely by Test Volume Growth
Natera's total revenue grew 58 percent year over year, driven by strong growth in total tests processed and in oncology test volume.
GenomeWeb Top 40 Index Grows 13 Percent in July, Outperforming Broader Market
The Dow Jones Industrial Average rose 4 percent, the Nasdaq declined by 1 percent, and the Nasdaq Biotech Index increased 7 percent during the month.
Natera Signatera MRD Test to Guide, Assess Treatment in Phase II Gastroesophageal Cancer Study
The Signatera ctDNA test will be used to evaluate the efficacy of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in the Phase II DECIPHER trial.
New Products Posted to GenomeWeb: Beckman Coulter, Natera, Epigenica, Micronbrane Medical
New products and services recently posted on GenomeWeb.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.
Feb 28, 2024